By George Ongkojoyo 
A multidisciplinary research team led by the Biocenter of Julius-Maximilians-Universität Würzburg (JMU), in a high-level collaboration with the Wellcome Sanger Institute in Cambridge, United Kingdom, has announced a landmark breakthrough in the understanding of Wilms’ tumors. These malignant kidney tumors, also known as nephroblastomas, represent the most common form of renal cancer in children, primarily affecting those under the age of five. By utilizing an extensive repository of samples from the German Wilms tumor biobank, the researchers have systematically decoded the hereditary and epigenetic predispositions that lead to the development of these life-threatening growths. The findings, published in the esteemed journal Genome Medicine, provide a comprehensive molecular roadmap that is expected to revolutionize genetic counseling, patient monitoring, and the early detection of at-risk individuals.
Wilms’ tumors have long been a focal point of pediatric oncology due to their rapid growth and the young age of the patients. While modern multimodal treatments—including chemotherapy, surgery, and radiation—have pushed survival rates to nearly 90%, the underlying biological triggers remained partially obscured for decades. The new study addresses this gap by analyzing a large cohort of patients to identify why certain children are predisposed to the disease. The research emphasizes that a significant portion of these tumors is not merely a result of random cellular errors but is rooted in specific genetic and epigenetic vulnerabilities present from birth or early development.
The German Wilms Tumor Biobank: A Three-Decade Scientific Legacy
The cornerstone of this research is the Wilms tumor biobank located at the JMU Biocenter. Established in 1994, the biobank has served as a central repository for biological material collected during the German Wilms tumor studies (GPOH-nephroblastoma trials). Between 1994 and 2022, samples from approximately 1,800 children were meticulously preserved and documented. This longitudinal effort provided the researchers with a statistically significant dataset that is virtually unparalleled in the field of pediatric rare diseases.
Within this vast collection, the team focused on specific high-risk subsets: 20 familial cases, where the tumor appeared in multiple generations or siblings, and 109 bilateral cases, where tumors developed in both kidneys. These specific categories are strong indicators of a constitutional genetic predisposition. By applying advanced genomic sequencing techniques to these samples, the researchers were able to identify the underlying genetic cause in over 90% of these high-risk cases. Lead author Dr. Jenny Wegert, a prominent scientist at the Department of Developmental Biochemistry at JMU, noted that the high identification rate underscores the power of large-scale biobanking in solving complex medical mysteries.
Validating the Two-Hit Hypothesis in Molecular Detail
The study provides definitive molecular evidence for a theory proposed more than half a century ago. In 1971, geneticist Alfred Knudson postulated the "two-hit hypothesis" to explain the occurrence of childhood cancers. He suggested that hereditary tumors result from two successive genetic events: an initial "hit" or mutation in a tumor suppressor gene that is inherited or occurs in the germline, followed by a second "hit" in the somatic tissue (the kidney) that disables the remaining functional copy of the gene.
The JMU and Sanger Institute researchers demonstrated this progression with unprecedented clarity. The primary actor in this process is the WT1 gene, a critical tumor suppressor involved in the development of the urogenital system. The study found that in many predisposed children, one copy of the WT1 gene is inactivated in every cell of the body. While this single mutation does not immediately cause a tumor, it carries significant health implications, including an increased risk of early-onset kidney failure and, in male patients, various genitourinary malformations.
The transition from a predisposed state to a malignant tumor requires a sequence of specific events. The researchers identified that the "second hit" involves the failure of the remaining functional WT1 copy within kidney cells. Simultaneously, the growth factor IGF2 (Insulin-like Growth Factor 2) becomes activated. This dual event triggers the formation of "nephrogenic rests"—pre-cancerous clusters of embryonic cells that persist in the kidney after birth. However, the final transformation into a malignant Wilms’ tumor requires a third catalyst: the activation of the WNT signaling pathway. This pathway, which governs cell growth and differentiation, essentially acts as the "on switch" for aggressive tumor proliferation.
The Role of Epigenetics: Genomic Imprinting and Mosaicism
One of the most significant revelations of the study involves the role of epigenetics, specifically genomic imprinting. Unlike traditional genetic mutations that involve changes to the DNA sequence, imprinting disorders involve "tags" on the DNA that dictate whether a gene is turned on or off. The researchers found that in approximately one-third of the children studied, the tumor was not caused by a classic inherited mutation but by a disturbance in the imprinting of the IGF2 gene.
Genomic imprinting is typically established during embryonic development and is not usually passed from parent to child in the traditional sense. Dr. Wegert explained that this finding has profound implications for families. "This means that in these cases, there is no increased risk for siblings, and the affected children do not pass on the tumor predisposition to their own future offspring," she stated. This discovery provides much-needed psychological relief to parents who often fear that a child’s cancer diagnosis implies a broader familial risk.
Furthermore, the study highlighted the phenomenon of "mosaicism." In many patients with IGF2 imprinting disorders, the body is a patchwork of normal cells and cells with epigenetic errors. If these "impaired" cells happen to be located in the kidney and subsequently acquire additional mutations, a tumor develops. This explains why some children develop Wilms’ tumors despite having no family history and no detectable mutations in their blood-derived DNA.
Chronology of Research and Collaboration
The journey to these findings spans nearly 30 years of clinical and laboratory work:
- 1994: The German Wilms tumor study begins a systematic collection of tumor and blood samples, establishing the biobank at JMU Würzburg under the auspices of the Society for Pediatric Oncology and Hematology (GPOH).
- 1994–2010: Focus remains on clinical outcomes and standardizing chemotherapy protocols, while the biobank grows into a significant national resource.
- 2011–2020: Advancements in Next-Generation Sequencing (NGS) allow for deeper genetic analysis. Collaboration with the Wellcome Sanger Institute begins, bringing world-class genomic infrastructure to the project.
- 2021–2023: Systematic analysis of familial and bilateral cases is conducted, focusing on the interplay between WT1, IGF2, and WNT signaling.
- 2024: Publication of the results in Genome Medicine, marking a turning point in the understanding of nephroblastoma predisposition.
Clinical Implications: A Call for Universal Screening
The practical applications of this research are immediate and far-reaching. Professor Manfred Gessler, Chair of Developmental Biochemistry at JMU and the head of the study, emphasized that the findings necessitate a change in how pediatric kidney tumors are managed in a clinical setting.
"Our findings impressively demonstrate that a significant proportion of childhood kidney tumors have a hereditary component," Professor Gessler remarked. He pointed out that identifying these genetic markers is crucial because patients with germline mutations are at a higher risk for secondary tumors later in life and are prone to early-onset kidney failure. By identifying these risks early, physicians can implement protective measures, such as nephron-sparing surgery, to preserve as much healthy kidney tissue as possible.
The study makes a compelling case for the implementation of broad molecular testing for all young patients diagnosed with Wilms’ tumors. Currently, genetic testing is often reserved for patients with a family history or bilateral disease. However, the discovery of mosaicism and the high frequency of WT1 and IGF2 involvement suggest that testing both blood and tumor samples should become a standard diagnostic procedure. Such screening would allow for:
- Tailored Monitoring: Children with a confirmed predisposition can undergo more frequent ultrasound screenings to detect recurrences or new tumors at the earliest, most treatable stage.
- Informed Counseling: Parents can receive accurate information regarding the risk to siblings and future generations.
- Long-term Renal Care: Early identification of WT1 mutations allows for proactive management of kidney health to delay or prevent the onset of renal failure.
Broader Impact on Pediatric Oncology and Genomic Medicine
The collaboration between JMU Würzburg and the Wellcome Sanger Institute serves as a model for international scientific cooperation. By combining a unique, long-term biological resource (the German biobank) with cutting-edge genomic technology, the team has solved a puzzle that individual institutions could not have addressed alone.
Beyond Wilms’ tumors, this study contributes to the broader understanding of "embryonal tumors"—cancers that arise from developmental errors in early life. The insights into how epigenetic mosaicism interacts with somatic mutations provide a template for researching other pediatric cancers, such as neuroblastoma or hepatoblastoma.
As genomic medicine continues to integrate into standard oncology, the ability to distinguish between truly hereditary risks and sporadic epigenetic events will become vital. The Würzburg study proves that even in cases where a disease appears "random," there is often a hidden molecular narrative that, once understood, can save lives and improve the quality of care for the youngest and most vulnerable patients.
The research was supported by various funding bodies, including the German Children’s Cancer Foundation (Deutsche Kinderkrebsstiftung), highlighting the importance of philanthropic and public support in advancing rare disease research. Moving forward, the JMU team plans to further investigate the WNT signaling pathway to determine if targeted therapies could be developed to interrupt the final stage of tumor development, potentially offering non-toxic alternatives to traditional chemotherapy.
